Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or New Hampshire for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to New Hampshire only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. New Hampshire (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Anthony Correnti (NPI 1336261577)

Field	Value
Entity Type	Individual
Organization	Anthony Correnti
Address	764 2nd St # Sy
City	Manchester
State	NH
ZIP	03102
Taxonomy	Ophthalmology Physician
NPI Enumerated	April 6, 2007

Payer Source	Total Paid
Medicare	$1.5M
Medicaid	$0

Key Findings

ANTHONY CORRENTI’s Medicare billing is concentrated in intravitreal biologic injections and ophthalmic diagnostic/office visits: the top three Medicare revenue codes (J2777, J0178, and 92014) together account for 86.1% of his total Medicare revenue, indicating a practice focused on medical retina care and routine ophthalmic follow-up rather than broad multispecialty procedures. J2777 (faricimab) alone generates $720.4K (47.3% of Medicare revenue) and J0178 (aflibercept) contributes $508K (33.4%), showing the business is highly dependent on anti-VEGF/faricimab therapies for revenue. The presence of substantial claims for 92014 (913 claims, $82.2K, 5.4%) and other evaluation/management codes (92012, 92235, 92250) supports a typical ophthalmology practice model where injection visits are paired with diagnostic imaging and established-patient exams.

Revenue concentration is pronounced: the precomputed top-3 share of 86.1% signals that a small set of drug-injection codes drive nearly all Medicare dollars for this provider. This concentration creates operational sensitivity to changes in reimbursement, drug mix, or utilization of intravitreal therapies, since J2777 and J0178 together constitute more than 80% of the Medicare revenue base. Ancillary services and office visits make up a small residual slice of revenue, underscoring the clinical/economic centrality of biologic injections in this practice.

Payer mix is effectively single-payer at present: lifetime Medicare revenue totals $1.5M while there is no Medicaid billing on file, so the provider appears to rely exclusively on Medicare for public-payer volume. This absence of Medicaid activity implies limited exposure to Medicaid rate pressures or rules and suggests the practice’s patient panel or billing arrangements skew toward Medicare beneficiaries. Analysts should treat this profile as Medicare-dominant when modeling reimbursement risk or contracting value.

Competitive standing for injection codes is mixed. For J2777 the provider ranks #394 of 2039 (81st percentile), which indicates typical, unremarkable national volume for faricimab relative to peers rather than a dominant market position. For J0178 the provider ranks #1585 of 3204 (50th percentile), placing him squarely in the middle of national peers for aflibercept volume, again consistent with a modest but established injector rather than a high-volume regional center.

Some diagnostic and E/M codes are used at notably above-typical national rates, signaling a robust follow-up and imaging workload: 92014 ranks #2011 of 35415 (94th percentile) and 92134 ranks #1087 of 26868 (96th percentile), both described as notably above typical national volume. These higher percentiles mean that while injection drug revenue dominates dollars, the provider also maintains above-average activity in comprehensive established-patient exams and retinal OCT imaging compared with national ophthalmologists, which supports a full-spectrum retina practice pattern.

Other billed services show typical or lower relative activity. Codes such as 67028 (intravitreal injection procedure) rank in the mid-range (#1501 of 4255, 65th percentile) and several imaging/photography codes (92250, 76512) sit around typical national volume. Low-ranking items like 92235 (2nd percentile) and minimal claims for J9035 (bevacizumab) indicate selective use of certain diagnostics and limited use of cheaper off-label injectables in Medicare billing. This mix suggests clinical preference or payer-driven selection toward specific FDA-approved biologics.

Tenure is long-standing: the NPI was enumerated on 2007-04-06 (approximately 19 years ago), indicating a stable, established practice presence in Manchester, NH. This duration supports interpretation of the billing profile as reflective of an experienced ophthalmologist with an entrenched referral and follow-up pattern rather than a transient or newly established clinician.

From an operational and payer-relations perspective, the clinic’s financial performance will be highly sensitive to changes in reimbursement for J2777 and J0178, given their outsized revenue shares. Contract negotiations, formulary placement, or shifts in clinical guidelines affecting use of faricimab or aflibercept could materially alter the provider’s Medicare revenue stream, so payers and network managers should treat these drug codes as the primary levers for financial impact.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

13 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J2777	Injection, faricimab‑svoa, 0.1 mg	24,840	$30	$720.4K
J0178	Injection, aflibercept, 1 mg	730	$690	$508K
92014	An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group…	910	$90	$82.2K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	910	$90	$80.1K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	1,950	$30	$58.5K
92012	For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any…	720	$70	$48.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	150	$90	$13.9K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	50	$70	$3.4K
J9035	Injection, bevacizumab, 10 mg	50	$50	$2.4K
92250	Code 92250 describes the taking of fundus photographs, that is, photographs of the posterior segment of the inner aspect of the eye, to document alterations in the optic nerve head, retinal vessels,…	80	$30	$2.3K

Showing 1–10 of 13

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 13 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. New Hampshire Distribution

Anthony Correnti — 3 of 13 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — New Hampshire

Full comparison — all codes billed, vs. state median

13 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J2777	4	10	13,440	$30	$563.5K
J0178	3	10	590	$680	$549.1K
67028	6	20	600	$90	$67K
92014	11	210	170	$80	$21.2K
99214	1,251	3,150	110	$80	$13.2K
J9035	8	10	150	$50	$10.6K
92012	1	70	60	$60	$8.2K
99213	1,842	2,900	70	$50	$6.9K
92134	2	170	60	$30	$5.2K
92250	84	170	80	$30	$3.5K

Showing 1–10 of 13

Related Providers

Other providers that share a Tax Identification Number (TIN) with Anthony Correnti, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Elliot Professional Services	NH	Internal Medicine Physician	$0	$12.8M
Kinley Beck	NH	Retina Specialist (Ophthalmology) Physician	$4.2M	$0
Maxwell Elia	NH	Ophthalmology Physician	$2.3M	$0
Ahad Fazelat	NH	Ophthalmology Physician	$2.1M	$0
Paul Degregorio	NH	Retina Specialist (Ophthalmology) Physician	$1.9M	$0
Gina Divenuti	NH	Hematology & Oncology Physician	$1M	$0
Frederick Briccetti	NH	Hematology & Oncology Physician	$861.3K	$0
Nancy Efferson-bonachea	NH	Ophthalmology Physician	$790.7K	$0
Nh Eye Associates PLLC	NH	Ophthalmology Physician	$0	$739K
Yu Cheng Zhao	MI	Ophthalmology Physician	$618.5K	$0

Nearby Providers

Other providers in the same ZIP code as Anthony Correnti, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Moore Center Services, Inc.	NH	Early Intervention Provider Agency	$0	$373.9M
Catholic Medical Center	NH	General Acute Care Hospital	$0	$19.8M
Manchester School District	NH	Local Education Agency (LEA)	$0	$4M
Amoskeag Health	NH	Federally Qualified Health Center (FQHC)	$0	$3.1M
Metro Treatment Of New Hampshire LP	NH	Methadone Clinic	$148.8K	$1.6M
Home For Butterflies, LLC	NH	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$1.4M
Catholic Medical Center	NH	Cardiovascular Disease Physician	$0	$489.4K
Amoskeag Health	NH	Federally Qualified Health Center (FQHC)	$0	$480.4K
Catholic Medical Center	NH	General Acute Care Hospital	$0	$472.3K
Cpte - Manchester, Inc.	NH	Physical Therapist	$0	$426.1K

Anthony Correnti — Billing Profile & Reimbursement Data

Sign up for Anthony Correnti — Billing Profile & Reimbursement Data policy alerts

Anthony Correnti — Billing Profile & Reimbursement Data

Sign up for Anthony Correnti — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References